Johnson & Johnson

NYSE JNJ

Johnson & Johnson Revenue Per Share for the Trailing 12 Months (TTM) ending September 29, 2024: USD 36.43

Johnson & Johnson Revenue Per Share is USD 36.43 for the Trailing 12 Months (TTM) ending September 29, 2024, a 7.66% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Johnson & Johnson Revenue Per Share for the Trailing 12 Months (TTM) ending October 01, 2023 was USD 33.84, a -3.67% change year over year.
  • Johnson & Johnson Revenue Per Share for the Trailing 12 Months (TTM) ending October 02, 2022 was USD 35.13, a 1.12% change year over year.
  • Johnson & Johnson Revenue Per Share for the Trailing 12 Months (TTM) ending October 03, 2021 was USD 34.74, a 13.09% change year over year.
  • Johnson & Johnson Revenue Per Share for the Trailing 12 Months (TTM) ending September 27, 2020 was USD 30.72, a 0.12% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
NYSE: JNJ

Johnson & Johnson

CEO Mr. Joaquin Duato
IPO Date Jan. 2, 1943
Location United States
Headquarters One Johnson & Johnson Plaza
Employees 131,900
Sector Health Care
Industries
Description

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Similar companies

MRK

Merck & Co., Inc.

USD 99.65

-1.32%

BMY

Bristol-Myers Squibb Company

USD 55.74

0.69%

PFE

Pfizer Inc.

USD 26.41

-1.46%

LLY

Eli Lilly and Company

USD 744.91

-6.59%

ABBV

AbbVie Inc.

USD 175.55

-0.67%

GILD

Gilead Sciences, Inc.

USD 91.00

1.18%

AMGN

Amgen Inc.

USD 267.10

-1.14%

StockViz Staff

January 15, 2025

Any question? Send us an email